Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2018 · 10-Q
Revenue$5.10M$5.10M+77.9% vs Q2 2017 Net Income$280.51K$280.51KN/M vs Q2 2017 EPS Diluted$0.02$0.02N/M vs Q2 2017 Gross Profit$2,862,723+127.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$431,471N/M Margins · derivedGross margin56.1%+12.2 pt vs Q2 2017
Operating margin5.4%+18.3 pt vs Q2 2017
Net margin5.5%+18.1 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 7, 2018 · 38 d after period end